{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-000283","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.281571+00:00","generated_at":"2026-05-24T06:37:53.346120+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oncocyte Q4 revenue $1.5M, GAAP loss $33.5M; transplant test on track for 2026 FDA authorization","bullets":["Q4 2024 pharma-services revenue $1.5M; full-year $1.9M; gross margin 40%.","GAAP loss from continuing ops $33.5M ($1.93/sh); non-GAAP operating loss $4.4M.","Recorded $41.9M intangible impairment (DetermaCNI $35.1M, DetermaIO $6.8M) offset by $13.7M contingent consideration gain.","Cash $10.3M at year-end; raised $29.1M in Feb 2025 offering; Bio-Rad holds ~9.66% stake.","Targeting FDA submission for kitted transplant assay GraftAssureDx by end 2025; authorization expected 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-000283","json":"https://secwatch.observer/filing/0001641172-25-000283.json","markdown":"https://secwatch.observer/filing/0001641172-25-000283.md","text":"https://secwatch.observer/filing/0001641172-25-000283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225000283/0001641172-25-000283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225000283/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:37:53.346120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}